Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Exclusion Criteria

• •1. Brain metastases with hemorrhage；
• •2. Meningeal involvement with metastatic carcinoma;
• •3. Subjects with ROS1 mutation, RET fusion positive, BRAF V600E mutation, NTRK fusion positive;
• •4. Participated in other clinical trials, or finish other clinical trials within 4 weeks;
• •5. Subject was received irradiation of brain;
• •6. Subjects have received solid organ or blood system transplantation;
• •7. Active autoimmune diseases requiring systemic treatment (such as the use of disease remission drugs, corticosteroids or immunosuppressants) occurred within 2 years before the first administration. Alternative therapy (such as thyroxine, insulin or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic therapy;
• •8. Subjects diagnosed immunodeficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy of non-related tumor within 7 days before the first dose; allowed physiological dose of glucocorticoid (≤10 mg/day Prednisone or equivalent);
• •9. Within 1 year before the first dose, there was a history of non-infectious pneumonia or interstitial lung disease requiring glucocorticoid treatment;
• •10. Subjects with grade II or above myocardial ischemia or myocardial infarction and poorly controlled arrhythmias (QTc interval \> 450 ms for males and QTc interval \> 470 ms for females). Subjects with grade III-IV cardiac insufficiency or with left ventricular ejection fraction (LVEF) less than 50% according to NYHA criteria;
• •11. Has known history of Human Immunodeficiency Virus (HIV)；
• •12. Untreated active hepatitis B；
• •13. Subjects have active hepatitis B；
• •14. Subjects have severe infections within 4 weeks of the first dose of study treatment；
• •15. Subjects with clinically significant bleeding symptoms or with obvious bleeding tendency in the first month;
• •16. Women who are pregnant or lactating；
• •17. Has known allergy to Camrelizumab, or pemetrexed, or paclitaxel, or albumin paclitaxel, or carboplatin, or cisplatin or any of accessories;
• •18. A prior malignancy other than NSCLC within 5 years before randomization，except carcinoma in situ of the cervix or basal cell carcinoma or squamous cell carcinoma of skin cancer with adequately treated, localized prostate cancer or ductal carcinoma in situ after radical resection.